RxDoctor Payments DataLook up a doctor →

Derek Larson, MD

Nephrology · Creve Coeur, MONPI 1588820096

Payments from drug & device makers

$604,987in general payments, 2019–2025

Across 914 payments — averaging $661.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$494K
  • Travere Therapeutics, Inc.$95K
  • Fresenius USA Marketing, Inc.$10K
  • Vifor Pharma, Inc.$4K
  • C. R. Bard, Inc. & Subsidiaries$327
  • Otsuka America Pharmaceutical, Inc.$303
  • plus $871 from 12 others

What the payments were for

  • Consulting fees$30,9565%
  • Speaking & faculty fees$504,75083%
  • Travel & lodging$47,8908%
  • Food & beverage$21,1673%
  • Education$2240%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$604,987 in reported general payments places this provider in the 95th percentile of 253 nephrology providers in Missouri.

See all nephrology providers in Missouri

Medicare billing

Part B allowed, 2024
$208,675
Medicare patients
581
Services billed
1,454

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol90$62,334
LokelmaSodium Zirconium Cyclosilicate13$9,487
Sevelamer Carbonate25$5,053
Sodium Bicarbonate36$3,097
Potassium Citrate ErPotassium Citrate20$2,568
Torsemide48$1,125
Labetalol Hcl22$747
Nifedipine ErNifedipine28$721
Calcitriol35$614
Amlodipine Besylate105$608
Potassium Chloride24$488
Losartan Potassium70$373
Lisinopril54$231
Allopurinol27$167
Gabapentin26$121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$493,801$71,821103 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 253 nephrology providers in Missouri.

Other nephrology in Creve Coeur

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →